At the crossroad of researches in relation with microbial virulence, drug resistance mechanisms, drug target characterization and medicinal/supramolecular chemistry

Our research covers a wide spectrum of activities incorporating the elucidation of viral and bacterial virulence and of antibacterial drug resistance mechanisms, the conception of molecules and polymers designed for potential therapeutic applications, the discovery of new antimicrobial activities, the supramolecular chemistry and the structural characterization of biomacromolecules

About us

logo unité microbiologie The Microbiology, Bioorganic and Macromolecular Chemistry (MBMC) unit of the ULB Faculty of Pharmacy is a multidisciplinary team, composed of members from different backgrounds and different areas of expertise.

The research group directed by Prof. Meyer is focused on supramolecular chemistry mainly based on halogen bonding and the preparation of polymers targeting functional materials and biomaterials.

The Dufrasne's research group is especially involved in solving problems related to the finding of new hits as receptor agonists/antagonists or enzyme inhibitors in collaboration with other teams working on molecular docking and protein crystallization at the University. Further developments can be made in-house such as lead generation, toxicological testing and drug preformulation to achieve animal testing.

The research group in Microbiology directed by Prof. Fontaine is mainly focused to fight two diseases: the cervical cancer due to the high-risk human papillomaviruses (HPV) and the tuberculosis mainly due to M. tuberculosis. In virology, we are currently studying the transcriptional HPV-16 promoter regulation and the integration mechanism of the viral genome but we are also working with the Universidad Mayor San Simon at Cochabamba in Bolivia to improve the cervical cancer screening and treatment. In mycobacteriology, we are studying the M. tuberculosis mechanisms allowing the pathogen to escape drug bactericidal activities and to develop virulence. This lead us to characterize new targets and discover new antituberculous drug candidates. Our laboratory can perform microbiological controls of pharmaceutic and cosmetic products, water, surface, antimicrobial and anti-biofilm activity testing (all possible under GLP, ISO 17025) with ATCC microorganisms (bacteria and fungi), either for pharmaceutical or cosmetic purposes.

Research of Wintjens'group is mainly concerned with, but not limited to, the characterization of interactions at atomic level between a protein target and drug-like small molecules with the primary aim of setting up a rational basis for the development of new drugs.

Team

Senior scientists

Prof. Franck MEYER
+32 (0) 2 650 51 96
franck.meyer@ulb.be

 

Prof. Véronique FONTAINE
+32 (0) 2 650 52 96
veronique.fontaine@ulb.be

Prof. René WINTJENS
+32 (0) 2 650 51 76
rene.wintjens@ulb.ac.be

Prof. François DUFRASNE
+32 (0) 2 650 52 35
dufrasne@ulb.be

 

 

Postdoctoral fellows and scientific collaborators

Dr. Gilles BERGER
+32 (0) 2 650 52 48
gilles.berger@ulb.ac.be

Dr. Michel GELBCKE
+32 (0) 2 650 52 35
michel.gelbcke@ulb.ac.be

 

PhD students

Mickaël MARLOYE
+32 (0) 2 650 52 48
mickael.marloye@ulb.ac.be

Pierre FRANGVILLE
+32 (0) 2 650 52 89
pierre.frangville@ulb.ac.be

Faustine RAVON
+32 (0) 2 650 53 18
faustine.ravon@ulb.ac.be

Gustavo ALLENDE
+32 (0) 2 650 53 18
gustavo.allende.larrain@ulb.ac.be

Ibrahima Sory SOW
+32 (0) 2 650 52 89
ibrahima.sory.sow@ulb.ac.be

Camille GROSSE
+32 (0) 2 526 72 80
camille.grosse@ulb.be

Danlei SUN
+32 (0) 2 650 51 74
danlei.sun@ulb.be

Michael VIG MERINO
+32 (0) 2 650 53 18
michael.vig.merino@ulb.ac.be

Rana EL NAKEEB
+32 (0) 2 650 52 06
rana.alnakib@student.umons.ac.be

Abdalkarim TANINA
+32 (0) 2 650 51 96
abed.tannina@vub.ac.be

Dong YANG
+32 (0) 2 650 51 74
dong.yang@ulb.ac.be

Zhiyu ZHOU
+32 (0) 2 650 51 74
zhiyu.zhou@ulb.be

 

Administrative, technical, management and/or specialized members

Naïma EL MANSOURI
+32 (0) 2 650 53 13
naima.el.manssouri@ulb.ac.be

Dr. Véronique MEGALIZZI
+32 (0) 2 650 51 74
veronique.megalizzi@ulb.be

Jérôme VANHEUVERZWIJN
+32 (0) 2 650 59 31
jerome.vanheuverzwijn@ulb.ac.be

Master students


Alumni

Ekaterina ALBERT (2015-2019)
PhD

Pedro SURRIABRE (2014-2019)
PhD

Janine RALET (1990-2018)
Technician

Paule BOUSSARD (2008-2019)
Professor

Ibaa Chikh ALARD (2013-2018)
PhD

Hugues FOUOTSA (2019)
Postdoc - University of Yaoundé I (Cameroon)

Shen ZENG (2014-2019)
PhD

Jingwen LIANG (2016-2018)
PhD

Céline RENS (2011-2018)
PhD


 
Skills

• Organic synthesis

• Supramolecular chemistry

• Polymer chemistry

• Functional materials

• NMR analysis

• Structure-activity relationships

• Mycobacteriology

• Antimicrobial and anti-biofilm activities

• Transcriptional regulation

• X-ray crystallography

• Structural biology

• Structure-based drug design

Publications
2020
  • Brito AS, Neuhäuser B, Wintjens R, Marini AM & Boeckstaens M (2020). Yeast filamentation signaling is connected to a specific substrate translocation mechanism of the Mep2 transceptor. PLoS Genet. in press
  • Yang D, Vandenbussche G, Vertommen D, Evrard D, Abskharon R, Cavalier JF, Berger G, Canaan S, Khan MS, Zeng S, Wohlkönig A, Prévost M, Soumillion P & Fontaine V (2020). Methyl arachidonyl fluorophosphonate inhibits Mycobacterium tuberculosis thioesterase TesA and globally affects vancomycin susceptibility. FEBS Lett. 594:79-93. pubmed
  • Villemagne B, Machelart A, Tran NC, Flipo M, Moune M, Leroux F, Piveteau C, Wohlkönig A, Wintjens R, Li X, Gref R, Brodin P, Déprez B, Baulard AR & Willand N (2020). Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity. ACS Infect. Dis. in press pubmed
2019
  • Surriabre P, Torrico A, Vargas T, Ugarte F, Rodriguez P & Fontaine V (2019). Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention. BMC Infect. Dis. 19:842. pubmed
  • Allende G, Surriabre P, Cáceres L, Bellot D, Ovando N, Torrico A, Calle P, Ascarrunz C, Alexander S, Bossens M, Fontaine V & Rodríguez P (2019). Evaluation of the self-sampling for cervical cancer screening in Bolivia. BMC Public Health 19:80. pubmed
  • Marloye M, Lawler SE & Berger G (2019). Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy. Pharm. Pat. Anal. pubmed
  • Prevet H, Moune M, Tanina A, Kemmer C, Herledan A, Frita R, Wohlkönig A, Bourotte M, Villemagne B, Leroux F, Gitzinger M, Baulard AR, Déprez B, Wintjens R, Willand N & Flipo M (2019). A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2. Eur. J. Med. Chem. 167:426-438. pubmed
  • Berger G, Marloye M & Lawler SE (2019). Pharmacological modulation of the STING pathway for cancer immunotherapy. Trends Mol. Med. 25:412-427. pubmed
  • Tanina A, Wohlkönig A, Soror SH, Flipo M, Villemagne B, Prevet H, Déprez B, Moune M, Perée H, Meyer F, Baulard AR, Willand N & Wintjens R (2019). A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR. Biochim. Biophys. Acta 1867:248-258. pubmed
  • Zeng S, Constant P, Yang D, Baulard A, Lefèvre P, Daffé M, Wattiez R & Fontaine V (2019). Cpn60.1 (GroEL1) contributes to mycobacterial crabtree effect: implications for biofilm formation. Front Microbiol. 10:1149. pubmed
  • Kim JH, Mertens RT, Agarwal A, Parkin S, Berger G & Awuah SG (2019). Direct intramolecular carbon(sp2)-nitrogen(sp2) reductive elimination from gold(iii). Dalton Trans. 48:6273-6282. pubmed
  • Zeng S, Soetaert K, Ravon F, Vandeput M, Bald D, Kauffmann JM, Mathys V, Wattiez R & Fontaine V (2019). Isoniazid bactericidal activity involves electron transport chain perturbation. Antimicrob. Agents Chemother. 63:e01841-18. pubmed
2018
  • Berger G, Soubhye J, Wintjens R, Robeyns K & Meyer F (2018). Crystal packing and theoretical analysis of halogen- and hydrogen-bonded hydrazones from pharmaceuticals. Evidence of type I and II halogen bonds in extended chains of dichloromethane. Acta Crystallogr. B74:618–627. pubmed
  • Dauchy C, Bautin N, Nseir S, Reboux G, Wintjens R, Le Rouzic O, Sendid B, Viscogliosi E, Le Pape P, Arendrup MC, Gosset P, Fry S & Fréalle E (2018). Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes. Indoor Air 28:298-306. pubmed
  • Mbosso Teinkela JE, Siwe Noundou X, Nguemfo EL, Meyer F, Wintjens R, Isaacs M, Mpondo Mpondo AE, Hoppe HC, Krause RWM & Azebaze AGB (2018). Biological activities of plant extracts from Ficus elastica and Selaginella vogelli: an antimalarial, antitrypanosomal and cytotoxity evaluation. Saudi J. Biol. Sci. 25:117-122. pubmed
  • Rens C, Laval F, Wattiez R, Lefèvre P, Dufrasne F, Daffé M & Fontaine V (2018). I3-Ag85 effect on phthiodiolone dimycocerosate synthesis. Tuberculosis 108:93-95. pubmed
  • Berger G & Lawler SE (2018). Novel non-nucleotidic STING agonists for cancer immunotherapy. Future Med. Chem. 10:2767-2769. pubmed
  • Rens C, Ceyssens PJ, Laval F, Lefèvre P, Mathys V, Daffé M & Fontaine V (2018). Aloe emodin reduces phthiodiolone dimycocerosate potentiating vancomycin susceptibility on mycobacteria. Indian J. Microbiol. 58:393-396. pubmed
  • Vernekar AA, Berger G, Czapar AE, Veliz FA, Wang DI, Steinmetz NF & Lippard SJ (2018). Speciation of phenanthriplatin and its analogs in the core of tobacco mosaic virus. J. Am. Chem. Soc. 140:4279-4287. pubmed
  • Sjollema J, Zaat SAJ, Fontaine V, Ramstedt M, Luginbuehl R, Thevissen K, Li J, van der Mei HC & Busscher HJ (2018). In vitro methods for the evaluation of antimicrobial surface designs. Acta Biomater. 70:12-24. pubmed
  • Berger G, Grauwet K, Zhang H, Hussey AM, Nowicki MO, Wang DI, Chiocca EA, Lawler SE & Lippard SJ (2018). Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. Cancer Letters 416:138-148. pubmed
  • Soubhye J, van Antwerpen P & Dufrasne F (2018). Targeting cytosolic phospholipase A2α for novel anti-inflammatory agents. Curr. Med. Chem. 25:2418-2447. pubmed
2017
  • Wohlkönig A, Remaut H, Moune M, Tanina A, Meyer F, Desroses M, Steyaert J, Willand N, Baulard A & Wintjens  R (2017). Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2. Biochem. Biophys. Res. Commun. 487:403-408. pubmed
  • Blondiaux N, Moune M, Desroses M, Frita R, Flipo M, Mathys V, Soetaert K, Kiass M, Delorme V, Djaout K, Trebosc V, Kemmer C, Wintjens R, Wohlkönig A, Antoine R, Huot L, Hot D, Coscolla M, Feldmann J, Gagneux S, Locht C, Brodin P, Gitzinger M, Déprez B, Willand N & Baulard AR (2017). Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. Science 355:1206-1211. pubmed
  • Surriabre P, Allende G, Prado M, Cáceres L, Bellot D, Torrico A, Ustariz K, Rojas S, Barriga J, Calle P, Villarroel L, Yañez RM, Baay M, Rodriguez P & Fontaine V (2017). Self-sampling for human papillomavirus DNA detection: a preliminary study of compliance and feasibility in BOLIVIA. BMC Womens Health 17:135. pubmed
  • Ngezahayo J, Ribeiro SO, Fontaine V, Hari L, Stévigny C & Duez P (2017). In vitro study of five herbs used against microbial infections in Burundi. Phytother. Res. 31:1571-1578. pubmed
  • Soubhye J, Chikh Alard I, Aldib I, Prévost M, Gelbcke M, De Carvalho A, Furtmüller PG, Obinger C, Flemmig J, Tadrent S, Meyer F, Rousseau A, Nève J, Mathieu V, Zouaoui Boudjeltia K, Dufrasne F & Van Antwerpen P (2017). Discovery of novel potent reversible and irreversible myeloperoxidase inhibitors using virtual screening procedure. J. Med. Chem. 60:6563-6586. pubmed
2016
  • Lim MY, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A, Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PC, Yeung BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA & Bifani P (2016). UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nat. Microbiol. 1:16166. pubmed
  • Mbosso Teinkela JE, Siwe Noundou X, Nguemfo EL, Meyer F, Djoukoue A, Van Antwerpen P, Ngouela S, Tsamo E, Mpondo Mpondo EA, Vardamides JC, Azebaze GA & Wintjens R (2016). Identification of compounds with anti-proliferative activity from the wood of Ficus elastica Roxb. ex Hornem. aerial roots. Fitoterapia 112:65-73. pubmed
  • Wintjens R, Bozon D, Belabbas K, MBou F, Girardet JP, Tounian P, Jolly M, Boccara F, Cohen A, Karsenty A, Dubern B, Carel JC, Azar-Kolakez A, Feillet F, Labarthe F, Gorsky AM, Horovitz A, Tamarindi C, Kieffer P, Lienhardt A, Lascols O, Di Filippo M & Dufernez F (2016). Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France. J. Lipid Res. 57:482-91. pubmed
  • Mbosso Teinkela JE, Assob Nguedia JC, Meyer F, Vouffo Donfack E, Lenta Ndjakou B, Ngouela S, Tsamo E, Adiogo D, Guy Blaise Azebaze A & Wintjens R (2016). In vitro antimicrobial and anti-proliferative activities of plant extracts from Spathodea campanulata, Ficus bubu, and Carica papaya. Pharm. Biol. 54:1086-95. pubmed
  • Bojilova ED, Weyn C, Antoine MH & Fontaine V (2016). Extrachromosomal HPV-16 LCR transcriptional activation by HDACi opposed by cellular differentiation and DNA integration. Oncotarget 7:75526-75538. pubmed
  • Rens C, Laval F, Daffé M, Denis O, Frita R, Baulard A, Wattiez R, Lefèvre P & Fontaine V (2016). Effects of lipid-lowering drugs on vancomycin susceptibility of mycobacteria. Antimicrob. Agents Chemother. 60:6193-9. pubmed
  • Zater H, Huet J, Fontaine V, Benayache S, Stévigny C, Duez P & Benayache F (2016). Chemical constituents, cytotoxic, antifungal and antimicrobial properties of Centaurea diluta Ait. subsp. algeriensis (Coss. & Dur.) Maire. Asian Pac. J. Trop. Med. 9:554-61. pubmed
  • Berger  G, Roeben  K, Soubhye  J, Wintjens  R & Meyer  F (2016). Halogen bonding in multi-connected 1,2,2-triiodo-alkene involving geminal and/or vicinal iodines: a crystallographic and DFT study. CrystEngComm. 18, 683.
  • Soubhye J, Gelbcke M, Van Antwerpen P, Dufrasne F, Boufadi MY, Nève J, Furtmüller PG, Obinger C, Zouaoui Boudjeltia K & Meyer F (2016). From dynamic combinatorial chemistry to in vivo evaluation of reversible and irreversible myeloperoxidase inhibitors. ACS Med. Chem. Lett. 8:206-210. pubmed
  • Marloye M, Berger G, Gelbcke M & Dufrasne F (2016). A survey of the mechanisms of action of anticancer transition metal complexes. Future Med. Chem. 8:2263-2286. pubmed
  • Aldib I, Gelbcke M, Soubhye J, Prévost M, Furtmüller PG, Obinger C, Elfving B, Alard IC, Roos G, Delporte C, Berger G, Dufour D, Zouaoui Boudjeltia K, Nève J, Dufrasne F & Van Antwerpen P (2016). Novel bis-arylalkylamines as myeloperoxidase inhibitors: design, synthesis, and structure-activity relationship study. Eur. J. Med. Chem. 123:746-762. pubmed
  • Soubhye J, Meyer F, Furtmüller P, Obinger C, Dufrasne F & Van Antwerpen P (2016). Characterization of chemical features of potent myeloperoxidase inhibitors. Future Med. Chem. 8:1163-77. pubmed
  • Soubhye J, Aldib I, Delporte C, Prévost M, Dufrasne F & Van Antwerpen P (2016). Myeloperoxidase as a target for the treatment of inflammatory syndromes: mechanisms and structure activity relationships of inhibitors. Curr. Med. Chem. 23:3975-4008. pubmed
  • Sá J, Czapla-Masztafiak J, Lipiec E, Kayser Y, Fernandes DL, Szlachetko J, Dufrasne F & Berger G (2016). Resonant X-ray emission spectroscopy of platinum(II) anticancer complexes. Analyst 141:1226-32. pubmed
2015
  • Soetaert K, Rens C, Wang XM, De Bruyn J, Lanéelle MA, Laval F, Lemassu A, Daffé M, Bifani P, Fontaine V & Lefèvre P (2015). Increased vancomycin susceptibility in mycobacteria: a new approach to identify synergistic activity against multidrug-resistant mycobacteria. Antimicrob. Agents Chemother. 59:5057-60. pubmed
  • Wang XM, Soetaert K, Peirs P, Kalai M, Fontaine V, Dehaye JP & Lefèvre P (2015). Biochemical analysis of the NAD+-dependent malate dehydrogenase, a substrate of several serine/threonine protein kinases of Mycobacterium tuberculosis. PLoS One 10:e0123327. pubmed
  • Boeckstaens M, Merhi A, Llinares E, Van Vooren P, Springael JY, Wintjens R & Marini AM (2015). Identification of a novel regulatory mechanism of nutrient transport controlled by TORC1-Npr1-Amu1/Par32. PLoS Genet. 11:e1005382. pubmed
  • Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R & Bifani P (2015). Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59:5316-23. pubmed
  • Dupré E, Herrou J, Lensink MF, Wintjens R, Vagin A, Lebedev A, Crosson S, Villeret V, Locht C, Antoine R & Jacob-Dubuisson F (2015). Virulence regulation with Venus flytrap domains: structure and function of the periplasmic moiety of the sensor-kinase BvgS. PLoS Pathog. 11:e1004700. pubmed
  • Mbosso E, Kamdem L, Nguedia JCA, Meyer F, Ebelle D, Lenta BN, Tchouankeu J, Tsamo E, Looze Y, Adiogo DDD, Azebaze GAB & Wintjens R (2015). In vitro evaluation of antimicrobial and antiproliferative activities for compounds isolated from the Ficus bubu Warb. (Moraceae) fruits: chemotaxonomic significance. Drug delivery letters 5:122-131.
  • Dufrasne F (2015). Technologies to develop new metal medicines. Drug Discov. Today Technol. 16:31-2. pubmed
  • Sá J, Czapla-Masztafiak J, Lipiec E, Kayser Y, Kwiatek W, Wood B, Deacon GB, Berger G, Dufrasne F, Fernandes DL & Szlachetko J (2015). The use of Resonant X-ray Emission Spectroscopy (RXES) for the electronic analysis of metal complexes and their interactions with biomolecules. Drug Discov. Today Technol. 16:1-6. pubmed
  • Soubhye J, Alard IC, van Antwerpen P & Dufrasne F (2015). Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis. Future Med. Chem. 7:1431-56. pubmed
  • Berger G, Fusaro L, Luhmer M, Czapla-Masztafiak J, Lipiec E, Szlachetko J, Kayser Y, Fernandes DL, Sá J, Dufrasne F & Bombard S (2015). Insights into the structure-activity relationships of chiral 1,2-diaminophenylalkane platinum(II) anticancer derivatives. J. Biol. Inorg. Chem. 20:841-53. pubmed
Collaborations
National
  • C. Vande Velde, Advanced Reactor Technology, Faculty of Applied Engineering, University of Antwerp, Hoboken
  • K. Robeyns, Institute of Condensed Matter and Nanosciences (IMCN), UCL, Louvain-la-Neuve
  • P. Dubois, J. M. Raquez,Center of Innovation and Research in Materials and Polymers (CIRMAP), UMons, Mons
  • J. Cornil, R. Lazzaroni, Laboratory of Chemistry for Novel Materials, UMons, Mons
  • K. Van Hecke, Inorganic and Physical Chemistry, Ghent University, Ghent
  • T. Verbiest, Molecular Imaging and Photonic, KUL, Leuven
  • G. Roos, General Chemistry, Vrije Universiteit Brussel, Brussels
  • R. Wattiez, Department of Proteomics and Microbiology, UMons, Mons
  • P. Soumillion, Institut des Sciences de la Vie, UCL, Louvain-la-Neuve
  • D. Vertommen, Institut de Duve, UCL, Louvain-la-Neuve
  • T. Leyssens, Molecular Chemistry, Materials and Catalysis, UCL, Louvain-la-Neuve
Europe
  • S. Clément, Institut Charles Gerhardt, Université de Montpellier 2, CMOS, Montpellier, France
  • F. Vidal, Laboratoire de Physicochimie des Polymères et des Interfaces, Université de Cergy Pontoise, France
  • B. Crousse, Laboratoire BioCIS associé au CNRS, Centre d’Etudes Pharmaceutiques, France
  • A. van der Lee, Institut Européen des Membranes, CNRS - UMR 5635, Université Montpellier 2, France
  • G. Resnati, P. Metrangolo, Dipartimento di Chimica, Materiali ed Ingegneria Chimica "G. Natta", Milano, Italy
  • H. Sirringhaus, Cavendish Laboratory, University of Cambridge, UK
  • V. Laudenbach, Faculté de Médecine, Université de Rouen, France
  • C. Obinger, Department of Chemistry, University of Natural Resources and Applied Life Sciences, Vienna, Austria
  • B. Elfving, Center for psykiatrisk forskning, Århus Universitetshospital, Risskov, Denmark
  • S. Bombard, INSERM, Unité INSERM UMR-S 1007, Homéostasie cellulaire et cancer, Université Paris Descartes, France
  • J. Sa, Department of Chemistry - Ångström Laboratory, Physical Chemistry , Uppsala Universitet, Uppsala, Sweden
  • J. Czapla‑Masztafiak, E. Lipiec, Henryk Niewodniczanski Institute of Nuclear Physics, Kraków, Poland
  • Y. Kayser, Paul Scherrer Institute (PSI), Villigen, Switzerland
  • J. Szlachetko, Institute of Physics, Jan Kochanowski University in Kielce, Poland
  • J. Flemmig, Institute for Medical Physics and Biophysics, Medical Faculty, University of Leipzig, Germany
  • M. Daffé, Institute of Pharmacology and Structural Biology, University of Toulouse, France
  • A. Baulard, Institut Pasteur de Lille, Centre Infection and Immunity of Lille, France
  • P. Supply, Institut Pasteur de Lille, Centre Infection and Immunity of Lille, France
  • P. Brodin, Institut Pasteur de Lille, Centre Infection and Immunity of Lille, France
  • P. Bertrand, UMR 7285 - Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Université de Poitiers, France
  • C. Abbadie, Initiation of Epithelial Cancers, Institut Pasteur de Lille, France
  • D. Bald, Faculty of Sciences, Structural Biology, Vrij University, Amsterdam, The Netherlands
  • N. Bayan, I2BC Institut de Biologie Cellulaire Intégrative, Université Paris Sud, France
  • F. Sobott, The Astbury Centre for Structural Molecular Biology, University of Leeds, UK
  • S. Canaan, Laboratoire d'Ingénierie des Systèmes Macromoléculaires, Marseilles, France
  • N. Willand, U1177 Drugs and Molecules for Living Systems, Université de Lille, France
Africa
  • J. E. T. Mbosso, Faculté de Médecine et des Sciences Pharmaceutiques (FMSP), Université de Douala, Cameroon
  • Y. Boufadi, Université Mostaganem, Algeria
North America
  • S. E. Lawler, Harvey Cushing Neuro-Oncology Laboratories, Harvard Medical School, Boston, Massachusetts, USA
South America
  • P. Rodriguez, Universidad Mayor San Simon, Faculty of Medicine, Cochabamba, Bolivia
Asia
  • P. Bifani, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
  • S. Zeng, T. Zhang, Guangzhou Institute of Biomedicine and Health, China
Australia


 
Thesis

2019

Ekaterina BOJILOVA "Impact of histone deacetylase inhibitors on the HPV-16 transcriptional activity and genomic integration"

Pedro SURRIABRE "Développement d’une stratégie adaptée à la situation bolivienne pour la détection des papillomavirus humains de haut risque"

Sheng ZENG "Mycobacterium bovis BCG chaperonin 60.1 contributes to adaptations under stresses : implication for escaping isoniazid bactericidal mechanism and for mycobacterial biofilm growth"

2018

Ibaa CHIKH ALARD “Development of novel multi-responsive materials characterized by potential controlled release properties”

• Céline RENS "Etude de la régulation transcriptionnelle de gènes nécessaires à la synthèse ou au transport de PDIM chez Mycobacterim bovis BCG et Mycobacterium tuberculosis"

 
Contact
Université Libre de Bruxelles
Plaine campus, CP 206/04
Building BC, level 4
Boulevard de Triomphe, access 2
1050 Brussels
Belgium
Emails:
        unit mbmc@ulb.be
        microbiology veronique.fontaine@ulb.be
        chemistry franck.meyer@ulb.be and dufrasne@ulb.be
        structural biology rene.wintjens@ulb.ac.be
Mis à jour le 18 août 2020